Exosomes derived from a mesenchymal-like endometrial regenerative cells ameliorate renal ischemia reperfusion injury through delivery of CD73.

IF 7.1 2区 医学 Q1 CELL & TISSUE ENGINEERING
Bo Shao, Hong-da Wang, Shao-Hua Ren, Qiang Chen, Zhao-Bo Wang, Yi-Ni Xu, Tong Liu, Cheng-Lu Sun, Yi-Yi Xiao, Hong-Yu Jiang, Yi-Cheng Li, Peng-Yu Zhao, Guang-Mei Yang, Xu Liu, Yu-Fan Ren, Hao Wang
{"title":"Exosomes derived from a mesenchymal-like endometrial regenerative cells ameliorate renal ischemia reperfusion injury through delivery of CD73.","authors":"Bo Shao, Hong-da Wang, Shao-Hua Ren, Qiang Chen, Zhao-Bo Wang, Yi-Ni Xu, Tong Liu, Cheng-Lu Sun, Yi-Yi Xiao, Hong-Yu Jiang, Yi-Cheng Li, Peng-Yu Zhao, Guang-Mei Yang, Xu Liu, Yu-Fan Ren, Hao Wang","doi":"10.1186/s13287-025-04275-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Renal ischemia reperfusion (I/R) injury is a major contributor to graft dysfunction and inflammation leading to graft loss. The deregulation of purinergic signaling has been implicated in the pathogenesis of renal I/R injury. CD73 and the generation of adenosine during purine metabolism to protect against renal I/R injury. A mesenchymal-like endometrial regenerative cell (ERC) has demonstrated a significant therapeutic effect on renal I/R injury. CD73 is a phenotypic marker of human endometrial regenerative cell exosomes (ERC-Exo). However, its immunosuppressive function in regulating purinergic metabolism has been largely neglected. Here, we investigate the protective effects and mechanism of ERC-Exo against renal I/R injury.</p><p><strong>Methods: </strong>Lentivirus-mediated CRISPR-Cas9 technology was employed to obtain CD73-specific knockout ERC-Exo (CD73<sup>-/-</sup>ERC-Exo). C57BL/6 mice who underwent unilateral ureteral obstruction were divided into the Untreated, ERC-Exo-treated, and CD73<sup>-/-</sup>ERC-Exo-treated groups. Renal function and pathological injury were assessed 3 days after renal reperfusion. The infiltration of CD4<sup>+</sup> T cells and macrophages was analyzed by flow cytometry and immunofluorescence staining in kidneys. CD73-mediated immunosuppressive activity of ERC-Exo was investigated by bone marrow-derived macrophages (BMDM) co-culture assay in vitro. Flow cytometry determined macrophage polarization. ELISA and Treg proliferation assays detected the function of macrophages. Furthermore, the role of the MAPK pathway in CD73-positive Exo-induced macrophage polarization was also elucidated.</p><p><strong>Results: </strong>Compared with Untreated and CD73<sup>-/-</sup>ERC-Exo-treated groups, CD73-positive Exo effectively improved the serum creatinine (sCr), blood urea nitrogen (BUN), and necrosis and detachment of tubular epithelial cells, necrosis and proteinaceous casts induced by ischemia. CD73 improved the capacity of ERC-Exo on CD4<sup>+</sup> T cell differentiation in the renal immune microenvironment. Surprisingly, ERC-Exosomal CD73 significantly decreased the populations of M1 cells but increased the proportions of M2 in kidneys. Furthermore, CD73-positive Exo markedly reduced the levels of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) and increased anti-inflammatory factors (IL-10) level in kidneys. ERC-Exosomal CD73 improved macrophage immunoregulatory function associated with the MAPK pathway (including ERK1/2 and p38 pathways), which exerted a potent therapeutic effect against renal I/R.</p><p><strong>Conclusions: </strong>These data collected insight into how ERC-Exo facilitated the hydrolysis of proinflammatory ATP to immunosuppressive ADO via CD73. CD73 is a critical modulator of the MAPK signaling pathway, inducing a polarization shift of macrophages towards an anti-inflammatory phenotype. This study highlights the significance of ERC-Exosomal CD73 in contributing to the therapeutic effects against renal I/R.</p>","PeriodicalId":21876,"journal":{"name":"Stem Cell Research & Therapy","volume":"16 1","pages":"148"},"PeriodicalIF":7.1000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948919/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cell Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13287-025-04275-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Renal ischemia reperfusion (I/R) injury is a major contributor to graft dysfunction and inflammation leading to graft loss. The deregulation of purinergic signaling has been implicated in the pathogenesis of renal I/R injury. CD73 and the generation of adenosine during purine metabolism to protect against renal I/R injury. A mesenchymal-like endometrial regenerative cell (ERC) has demonstrated a significant therapeutic effect on renal I/R injury. CD73 is a phenotypic marker of human endometrial regenerative cell exosomes (ERC-Exo). However, its immunosuppressive function in regulating purinergic metabolism has been largely neglected. Here, we investigate the protective effects and mechanism of ERC-Exo against renal I/R injury.

Methods: Lentivirus-mediated CRISPR-Cas9 technology was employed to obtain CD73-specific knockout ERC-Exo (CD73-/-ERC-Exo). C57BL/6 mice who underwent unilateral ureteral obstruction were divided into the Untreated, ERC-Exo-treated, and CD73-/-ERC-Exo-treated groups. Renal function and pathological injury were assessed 3 days after renal reperfusion. The infiltration of CD4+ T cells and macrophages was analyzed by flow cytometry and immunofluorescence staining in kidneys. CD73-mediated immunosuppressive activity of ERC-Exo was investigated by bone marrow-derived macrophages (BMDM) co-culture assay in vitro. Flow cytometry determined macrophage polarization. ELISA and Treg proliferation assays detected the function of macrophages. Furthermore, the role of the MAPK pathway in CD73-positive Exo-induced macrophage polarization was also elucidated.

Results: Compared with Untreated and CD73-/-ERC-Exo-treated groups, CD73-positive Exo effectively improved the serum creatinine (sCr), blood urea nitrogen (BUN), and necrosis and detachment of tubular epithelial cells, necrosis and proteinaceous casts induced by ischemia. CD73 improved the capacity of ERC-Exo on CD4+ T cell differentiation in the renal immune microenvironment. Surprisingly, ERC-Exosomal CD73 significantly decreased the populations of M1 cells but increased the proportions of M2 in kidneys. Furthermore, CD73-positive Exo markedly reduced the levels of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) and increased anti-inflammatory factors (IL-10) level in kidneys. ERC-Exosomal CD73 improved macrophage immunoregulatory function associated with the MAPK pathway (including ERK1/2 and p38 pathways), which exerted a potent therapeutic effect against renal I/R.

Conclusions: These data collected insight into how ERC-Exo facilitated the hydrolysis of proinflammatory ATP to immunosuppressive ADO via CD73. CD73 is a critical modulator of the MAPK signaling pathway, inducing a polarization shift of macrophages towards an anti-inflammatory phenotype. This study highlights the significance of ERC-Exosomal CD73 in contributing to the therapeutic effects against renal I/R.

来自间充质样子宫内膜再生细胞的外泌体通过递送CD73改善肾缺血再灌注损伤。
背景:肾缺血再灌注(I/R)损伤是移植物功能障碍和炎症导致移植物损失的主要原因。嘌呤能信号的失调与肾I/R损伤的发病机制有关。嘌呤代谢过程中CD73和腺苷的产生对肾I/R损伤的保护作用。间充质样子宫内膜再生细胞(ERC)对肾I/R损伤有显著的治疗作用。CD73是人子宫内膜再生细胞外泌体(ERC-Exo)的表型标志物。然而,其调节嘌呤能代谢的免疫抑制功能在很大程度上被忽视。本研究探讨ERC-Exo对肾I/R损伤的保护作用及其机制。方法:采用慢病毒介导的CRISPR-Cas9技术获得CD73特异性敲除ERC-Exo (CD73-/-ERC-Exo)。将单侧输尿管梗阻的C57BL/6小鼠分为未治疗组、erc - exo治疗组和CD73-/- erc - exo治疗组。肾再灌注后3 d评估肾功能及病理损伤。用流式细胞术和免疫荧光染色分析肾组织中CD4+ T细胞和巨噬细胞的浸润情况。采用体外骨髓源性巨噬细胞(bone marrow macrophages, BMDM)共培养法研究cd73介导的ERC-Exo免疫抑制活性。流式细胞术检测巨噬细胞极化。ELISA和Treg增殖法检测巨噬细胞的功能。此外,MAPK通路在cd73阳性外显子诱导的巨噬细胞极化中的作用也被阐明。结果:与未处理组和CD73-/- erc -Exo处理组相比,CD73-阳性Exo处理组可有效改善大鼠血清肌酐(sCr)、血尿素氮(BUN)水平,改善缺血所致小管上皮细胞坏死、脱离、坏死及蛋白样铸型。CD73提高ERC-Exo在肾免疫微环境中对CD4+ T细胞分化的能力。令人惊讶的是,erc -外泌体CD73显著降低了M1细胞的数量,但增加了肾脏中M2细胞的比例。此外,cd73阳性Exo显著降低肾脏促炎因子(IL-1β、IL-6和TNF-α)水平,增加抗炎因子(IL-10)水平。erc -外泌体CD73改善与MAPK通路(包括ERK1/2和p38通路)相关的巨噬细胞免疫调节功能,对肾I/R具有有效的治疗作用。结论:这些数据收集了ERC-Exo如何通过CD73促进促炎ATP水解为免疫抑制ADO的见解。CD73是MAPK信号通路的关键调节剂,可诱导巨噬细胞向抗炎表型极化转移。本研究强调了erc -外泌体CD73在治疗肾I/R中的重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Stem Cell Research & Therapy
Stem Cell Research & Therapy CELL BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
13.20
自引率
8.00%
发文量
525
审稿时长
1 months
期刊介绍: Stem Cell Research & Therapy serves as a leading platform for translational research in stem cell therapies. This international, peer-reviewed journal publishes high-quality open-access research articles, with a focus on basic, translational, and clinical research in stem cell therapeutics and regenerative therapies. Coverage includes animal models and clinical trials. Additionally, the journal offers reviews, viewpoints, commentaries, and reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信